These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15252704)

  • 21. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
    J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder.
    Korb AS; Hunter AM; Cook IA; Leuchter AF
    Psychiatry Res; 2011 Jun; 192(3):188-94. PubMed ID: 21546222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
    Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL
    J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.
    Hunter AM; Ravikumar S; Cook IA; Leuchter AF
    Acta Psychiatr Scand; 2009 Apr; 119(4):266-73. PubMed ID: 19077131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Midline and right frontal brain function as a physiologic biomarker of remission in major depression.
    Cook IA; Hunter AM; Abrams M; Siegman B; Leuchter AF
    Psychiatry Res; 2009 Nov; 174(2):152-7. PubMed ID: 19853417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia.
    Hellerstein DJ; Yanowitch P; Rosenthal J; Samstag LW; Maurer M; Kasch K; Burrows L; Poster M; Cantillon M; Winston A
    Am J Psychiatry; 1993 Aug; 150(8):1169-75. PubMed ID: 8328559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
    Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
    Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression.
    Korb AS; Hunter AM; Cook IA; Leuchter AF
    Clin Neurophysiol; 2009 Jul; 120(7):1313-9. PubMed ID: 19539524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of improved mood over time in clinical trials for major depression.
    Marie-Mitchell A; Leuchter AF; Chou CP; James Gauderman W; Azen SP
    Psychiatry Res; 2004 Jun; 127(1-2):73-84. PubMed ID: 15261707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.